COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (NCT07449936)

🧪 Interventions in This Study

• EYP-1901 (DRUG)
• Aflibercept (2.0 mg) (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (73 Sites)

Showing the first 25 of 73 sites.

• California Retina Consultants — Bakersfield, California
• The Retina Partners — Encino, California
• Global Research Management, Inc. — Glendale, California
• Northern California Retina Vitreous Associates Medical Group INC. — Mountain View, California
• Retina Consultants of San Diego — Poway, California
• California Eye Specialists Medical Group, Inc. — Redlands, California
• Retinal Consultants Medical Group - Parkcenter Drive — Sacramento, California
• Retinal Consultants Medical Group — Sacramento, California
• Retina Consultants of Southern Colorado — Colorado Springs, Colorado
• Colorado Retina Associates — Lakewood, Colorado
• Advanced Research LLC Sibia Eye Institute — Boynton Beach, Florida
• Advance Medical Research Group, Inc — Deerfield Beach, Florida
• Eye Associates of Pinellas — Pinellas Park, Florida
• Retina Vitreous Associates of Florida - Saint Petersburg — St. Petersburg, Florida
• Southern Vitreoretinal Associates — Tallahassee, Florida
• Retina Specialists of Tampa — Wesley Chapel, Florida
• Georgia Retina — Marietta, Georgia
• Retina Consultants of Hawaii — ‘Aiea, Hawaii
• Red River Research Partners — Plainfield, Illinois
• Midwest Eye Institute - Carmel — Carmel, Indiana
• Haik Humble Eye Center — West Monroe, Louisiana
• Johns Hopkins Medicine - The Johns Hopkins Hospital Campus - Wilmer Eye Institute — Baltimore, Maryland
• Retina Group of Washington — Chevy Chase, Maryland
• Cumberland Valley Retina Consultants — Hagerstown, Maryland
• Retina Specialists - Towson — Towson, Maryland

📞 Contact the Study Coordinator

Phone: (833) 393-7646

Email: rribeiro@eyepoint.bio

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Diabetic Macular Edema

• Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT) — Beverly Hills, California
• 4D-150 in Patients With Diabetic Macular Edema — Hagerstown, Maryland
• Mean Visual Acuity Changes Following Five Injections of Aflibercept — Hamilton, Ontario
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME) — Mesa, Arizona
• A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema — Phoenix, Arizona
• A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME — Mesa, Arizona

Explore by condition: All Diabetic Macular Edema clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.